Zhongzhi Pharmaceutical Holdings Limited provided consolidated earnings guidance for the year ended December 31, 2022. It is expected that the Group will record a significant increase in the net profit with net profit of around RMB 110.0 million for Fiscal 2022 as compared to the net profit of approximately RMB 52.4 million for the year ended 31 December 2021 (Fiscal 2021).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.2 HKD | +0.84% | 0.00% | -15.49% |
25/03 | Zhongzhi Pharmaceutical's Attributable Jumps in 2023 | MT |
22/03 | Zhongzhi Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 13 June 2024 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.49% | 13Cr | |
+21.28% | 4.44TCr | |
+24.60% | 2.3TCr | |
+17.89% | 1.51TCr | |
+12.87% | 1.31TCr | |
+44.67% | 1.19TCr | |
-8.33% | 698.92Cr | |
-0.05% | 678.76Cr | |
-8.87% | 572.55Cr | |
+12.22% | 551.54Cr |
- Stock Market
- Equities
- 3737 Stock
- News Zhongzhi Pharmaceutical Holdings Limited
- Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022